Dr. Uwe Gottschalk, vice president of purification technologies at Sartorius AG (Goettingen, Germany, www.sartorious.com) and member of BioPharm International's editorial advisory board, will now also be a lecturer at the University of Duisburg-Essen, for the first Master's degree program in pharmaceutical medicine.
Dr. Uwe Gottschalk, vice president of purification technologies at Sartorius AG (Goettingen, Germany, www.sartorious.com) and a member of BioPharm International’s editorial advisory board, will now also be a lecturer at the University of Duisburg-Essen, for the first Master’s degree program in pharmaceutical medicine. This internationally focused program is accredited throughout Germany and is designed to qualify medical and scientific students for managerial positions in research, development, approvals, and marketing of pharmaceuticals and medical products. Based in Goettingen, Germany, Dr. Gottschalk will manage the biotechnology study module and lecture on the development and production aspects of biopharmaceutical products.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.